Background/Aim: Numerous trials have described a wide variation of metabolic
complications associated with the mammalian target of rapamycin inhibitors (mTORi). This …

Background mTOR inhibitors are now approved by regulatory agencies for the treatment of a
variety of malignancies. The risk of metabolic complications with these agents is not well …

Background. mTOR inhibitors are currently used in the treatment of solid malignancies.
Since their approval, several cases of pulmonary toxicity (PT) have been described. This …

Background Inhibition of the mammalian target of rapamycin (mTOR) is an established
treatment for multiple malignancies. We carried out an up-to-date meta-analysis to …

Using mTOR inhibitors (mTORi) as anticancer drugs led to hyperglycemia (12–50%) and
hyperlipidemia (7–73%) in phase-III trials. These high rates require adapted treatment in …

Background Two novel mammalian targets of rapamycin (mTOR) inhibitors everolimus and
temsirolimus are now approved by regulatory agencies and have been widely investigated …

Background: Mammalian target of rapamycin (mTOR) inhibitors, temsirolimus and
everolimus, are currently approved for the treatment of several malignancies. Hematological …

Introduction: Hepatocellular carcinoma (HCC) is a major health problem worldwide. Several
molecular pathways involved in HCC growth and progression have recently been identified …

3091 Background: Hyperglycemia and hypertriglyceridemia are mechanism-based toxicities
of mammalian target of rapamycin (mTOR) inhibitors, but have not been intensively studied …

The common dysregulation of the mTOR signaling pathway in tumor cells makes it a key
target in oncotherapy. To better understand the effects of mTOR inhibitors, we analyzed 32 …